In vitro inhibition of fibrinolysis by apolipoprotein(a) and lipoprotein(a) is size- and concentration-dependent

Clinical Chemistry and Laboratory Medicine

Volumn 42, Issue 9, 2004, Pages 1013-1019

  Knapp, Jean Pierre ^a   Herrmann, Wolfgang ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Fibrinolysis; Inhibition; Lipoprotein(a); Phenotype; Thrombosis

Indexed keywords

APOLIPOPROTEIN A; LIPOPROTEIN A; PLASMIN;

ARTICLE; CONTROLLED STUDY; FIBRINOLYSIS; HUMAN; IN VITRO STUDY; KRINGLE DOMAIN; MOLECULAR MODEL; MOLECULAR SIZE; MONITORING; PHENOTYPE; PRIORITY JOURNAL; STANDARDIZATION; TIME;

ANTIFIBRINOLYTIC AGENTS; APOLIPOPROTEINS; APOPROTEIN(A); FIBRINOLYSIS; HUMANS; LIPOPROTEIN(A); PHENOTYPE; PLASMIN; PLASMINOGEN;

EID: 4744348369     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2004.205     Document Type: Article

References (44)

1. Berg K. A new serum type system in man - the Lp system. Acta Pathol Micribiol Scand 1963;59:369-82.
2. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM Jr. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986;74:758-65.
3. Herrmann W, Hanf S, Schmidt H, Kostner GM. Lp(a) - ein besonderes Lipoprotein mit atherogener Wirkung. Z Klin Med 1987;42:1333-6.
4. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. Br Med J 1990;301:1248-51.
5. Wiklund O, Angelin B, Olofsson SO, Eriksson M, Fager G, Berglund L, et al. Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia. Lancet 1990;335:1360-3.
6. Kark JD, Sandholzer C, Friedlander Y, Utermann G. Plasma Lp(a), apolipoprotein(a) isoforms and acute myocardial infarction in men and women: a case-control study in the Jerusalem population. Atherosclerosis 1993;98:139-51.
7. Wild SH, Fortmann SP, Marcovina SM. A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. Arterioscler Thromb Vasc Biol 1997;17:239-45.
8. Koschinsky ML, Marcovina SM. Lipoprotein(a): structural implications for pathophysiology. Int J Clin Lab Res 1997;27:14-23.
9. Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for coronary artery disease. Am J Cardiol 1998;82:57U-66U.
10. Cambillau M, Simon A, Amar J, Giral P, Atger V, Segond P, et al. Serum Lp(a) as a discriminant marker of early atherosclerotic plaque at three extracoronary sites in hypercholesterolemic men. The PCVMETRA Group. Arterioscler Thromb 1992;12:1346-52.
11. Genest J Jr, McNamara JR, Ordovas JM, Jenner JL, Silberman SR, Anderson KM, et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol 1992;19:792-802.
12. Nowak-Gottl U, Schobess R, Kurnik K, Schwabe D, Fleischhack G, Junker R. Elevated lipoprotein(a) concentration is an independent risk factor of venous thromboembolism. Blood 2002;99:3476-7.
13. Loscalzo J. Lipoprotein(a). A unique risk factor for atherothrombotic disease. Arteriosclerosis 1990;10:672-9.
14. Rouy D, Grailhe P, Nigon F, Chapman J, Angles-Cano E. Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue- type plasminogen activator. In vitro studies in a plasma milieu. Arterioscler Thromb 1991;11:629-38.
15. Hughes SD, Lou XJ, Ighani S, Verstuyft J, Grainger DJ, Lawn RM, et al. Lipoprotein(a) vascular accumulation in mice. In vivo analysis of the role of lysine binding sites using recombinant adenovirus. J Clin Invest 1997;100:1493-500.
16. Gazzaruso C, Geroldi D, Garzaniti A, Falcone C, Fratino P, Finardi G, et al. Apolipoprotein(a) phenotypes as genetic markers of coronary atherosclerosis severity. Int J Cardiol 1998;64:277-84.
17. Hervio L, Chapman MJ, Thillet J, Loyau S, Angles-Cano E. Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis? Blood 1993;82:392-7.
18. Armstrong VW, Harrach B, Robenek H, Helmhold M, Walli AK, Seidel D. Heterogeneity of human lipoprotein Lp[a]: cytochemical and biochemical studies on the interaction of two Lp[a] species with the LDL receptor. J Lipid Res 1990;31:429-41.
19. Halvorsen S, Skjonsberg OH, Berg K, Ruyter R, Godal HC. Does Lp(a) lipoprotein inhibit the fibrinolytic system? Thromb Res 1992;68:223-32.
20. Mao SJ, Tucci MA. Lipoprotein(a) enhances plasma clot lysis in vitro. FEBS Lett 1990;267:131-4.
21. Liu J, Harpel PC, Gurewich V. Fibrin-bound lipoprotein(a) promotes plasminogen binding but inhibits fibrin degradation by plasmin. Biochemistry 1994;33:2554-60.
22. Testa R, Marcovina SM. The rate of plasmin formation after in vitro clotting is inversely related to lipoprotein(a) plasma levels. Int J Clin Lab Res 1999;29:128-32.
23. Edelberg JM, Gonzalez-Gronow M, Pizzo SV. Lipoprotein a inhibits streptokinase-mediated activation of human plasminogen. Biochemistry 1989;28:2370-4.
24. Mooser V, Marcovina SM, White AL, Hobbs HH. Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine. J Clin Invest 1996;98:2414-24.
25. Mooser V, Seabra MC, Abedin M, Landschulz KT, Marcovina S, Hobbs HH. Apolipoprotein(a) kringle 4-containing fragments in human urine. Relationship to plasma levels of lipoprotein(a). J Clin Invest 1996;97:858-64.
26. Kostner KM, Maurer G, Huber K, Stefenelli T, Dieplinger H, Steyrer E, et al. Urinary excretion of apo(a) fragments. Role in apo(a) catabolism. Arterioscler Thromb Vasc Biol 1996;16:905-11.
27. Kostner KM, Huber K, Stefenelli T, Rinner H, Maurer G. Urinary apo(a) discriminates coronary artery disease patients from controls. Atherosclerosis 1997;129:103-10.
28. Oida K, Takai H, Maeda H, Takahashi S, Shimada A, Suzuki J, et al. Apolipoprotein(a) is present in urine and its excretion is decreased in patients with renal failure. Clin Chem 1992;38:2244-8.
29. Trenkwalder E, Gruber A, Konig P, Dieplinger H, Kronenberg F. Increased plasma concentrations of LDL-unbound apo(a) in patients with end-stage renal disease. Kidney Int 1997;52:1685-92.
30. Mooser V, Marcovina SM, Wang J, Hobbs HH. High plasma levels of apo(a) fragments in Caucasians and African-Americans with end-stage renal disease: implications for plasma Lp(a) assay. Clin Genet 1997;52:387-92.
31. Herrmann W, Quast S, Wolter K, Eger H, Kießig ST, Hahmann H, et al. Determination of free apo(a) in serum by immunoassay and its significance for risk assessment in patients with CAD. Clin Chem Lab Med 1999;37:21-8.
32. Lawn RM, Wade DP, Hammer RE, Chiesa G, Verstuyft JG, Rubin EM. Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature 1992; 360:670-2.
33. Scanu AM, Miles LA, Fless GM, Pfaffinger D, Eisenbart J, Jackson E, et al. Rhesus monkey lipoprotein(a) binds to lysine Sepharose and U937 monocytoid cells less efficiently than human lipoprotein(a). Evidence for the dominant role of kringle 4(37). J Clin Invest 1993;91:283-91.
34. Biemond BJ, Friederich PW, Koschinsky ML, Levi M, Sangrar W, Xia J, et al. Apolipoprotein(a) attenuates endogenous fibrinolysis in the rabbit jugular vein thrombosis model in vivo. Circulation 1997;96:1612-5.
35. Sangrar W, Gabel BR, Boffa MB, Walker JB, Hancock MA, Marcovina SM, et al. The solution phase interaction between apolipoprotein(a) and plasminogen inhibits the binding of plasminogen to a plasmin-modified fibrinogen surface. Biochemistry 1997;36:10353-63.
36. Edelstein C, Italia JA, Scanu AM. Polymorphonuclear cells isolated from human peripheral blood cleave lipoprotein(a) and apolipoprotein(a) at multiple interkringle sites via the enzyme elastase. Generation of mini-Lp(a) particles and apo(a) fragments. J Biol Chem 1997; 272:11079-87.
37. Sattler W, Kostner GM, Waeg G, Esterbauer H. Oxidation of lipoprotein Lp(a). A comparison with low-density lipoproteins. Biochim Biophys Acta 1991;1081:65-74.
38. Fless GM, ZumMallen ME, Scanu AM. Isolation of apolipoprotein(a) from lipoprotein(a). J Lipid Res 1985;26:1224-9.
39. Kang C, Dominguez M, Loyau S, Miyata T, Durlach V, Angles-Cano E. Lp(a) particles mold fibrin-binding properties of apo(a) in size- dependent manner: a study with different-length recombinant apo(a), native Lp(a), and monoclonal antibody. Arterioscler Thromb Vasc Biol 2002;22:1232-8.
40. Kraft HG, Lingenhel A, Bader G, Kostner GM, Utermann G. The relative electrophoretic mobility of apo(a) isoforms depends on the gel system: proposal of a nomenclature for apo(a) phenotypes. Atherosclerosis 1996;125:53-61.
41. Kottke BA. Problems in the measurement of Lp(a) (millimoles per liter versus milligrams percent). J Am Coll Cardiol 2001;38:1584-5.
42. Sandholzer C, Saha N, Kark JD, Rees A, Jaross W, Dieplinger H, et al. Apo(a) isoforms predict risk for coronary heart disease. A study in six populations. Arterioscler Thromb 1992;12:1214-26.
43. Jurgens G, Taddei-Peters WC, Koltringer P, Petek W, Chen Q, Greilberger J, et al. Lipoprotein(a) serum concentration and apolipoprotein(a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. Stroke 1995;26:1841-8.
44. Farrer M, Game FL, Albers CJ, Neil HA, Winocour PH, Laker MF, et al. Coronary artery disease is associated with increased lipoprotein(a) concentrations independent of the size of circulating apolipoprotein(a) isoforms. Arterioscler Thromb 1994;14:1272-83.